Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glembatumumab vedotin in advanced squamous cell lung cancer
NCT02713828Phase 2Terminated
- Sponsor
- PrECOG
- Start
- Apr 2016
- Primary completion
- May 2018
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of glembatumumab vedotin in lung squamous cell carcinoma (LSCC), sponsored by PrECOG. Primary endpoints: Maximum Tolerated Dose at 42 days and Objective Response Rate at 40 months. Started Apr 2016; status: terminated.
02
Drugs
glembatumumab vedotin
03
Conditions
lung squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on NCT02713828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713828.